Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution

The approval of poly(ADP-ribose) polymerase (PARP) inhibitor AZD2281 in 2014 marked the successful establishment of the therapeutic strategy targeting homologous recombination repair defects of cancers in the clinic. However, AZD2281 has poor water solubility, low tissue distribution and relatively...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Jin-Xue, Wang, Meng, Huan, Xia-Juan, Chen, Chuan-Huizi, Song, Shan-Shan, Wang, Ying-Qing, Liao, Xue-Mei, Tan, Cun, He, Qian, Tong, Lin-Jiang, Wang, Yu-Ting, Li, Xiao-Hua, Su, Yi, Shen, Yan-Yan, Sun, Yi-Ming, Yang, Xin-Ying, Chen, Yi, Gao, Zhi-Wei, Chen, Xiao-Yan, Xiong, Bing, Lu, Xiu-Lian, Ding, Jian, Yang, Chun-Hao, Miao, Ze-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354820/
https://www.ncbi.nlm.nih.gov/pubmed/27926532
http://dx.doi.org/10.18632/oncotarget.13749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354820/
https://www.ncbi.nlm.nih.gov/pubmed/27926532
http://dx.doi.org/10.18632/oncotarget.13749

Ejemplares similares